About this trial
This study evaluates whether lactoferrin, a naturally occurring protein with anti-inflammatory and antioxidant properties, can improve pain control after cesarean section. Effective management of postoperative pain is essential to support maternal recovery, mobility, and the ability to care for the newborn, while minimizing reliance on opioid medications and their associated side effects.
In this randomized, double-blind, placebo-controlled trial, women undergoing elective cesarean section will receive either oral lactoferrin or a matching placebo in addition to standard postoperative analgesia. Lactoferrin will be administered starting before surgery and continued for 48 hours after delivery.
The study will assess whether lactoferrin reduces postoperative pain intensity and opioid consumption, and improves recovery outcomes such as time to mobilization, patient satisfaction, and incidence of common postoperative symptoms. Safety and tolerability will also be evaluated.
Eligibility criteria
Qualifiers
Referred to elective (non-emergency) cesarean section
Undergoing spinal anesthesia) with American Society of Anesthesiologists (ASA) classification I and II
Term gestational age
Disqualifiers
History of seizures
Pre-eclampsia or eclampsia
Hypertension
Use of narcotic painkillers for 24 h before the intervention
Trial design
Treatments tested in this trial
- Lactoferrin
- Placebo